EX-10.34S-1·CIK 2066836·0001062993-26-006205

Board Member Agreement

View original filing on SEC EDGAR → ·  seen Nov 19, 2026, 16:31 EST


CERTAIN INDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

CONEXEU SCIENCES
BOARD MEMBER AGREEMENT

This Board Member Agreement ("Agreement") is made and entered into as of November 19, 2026, by and between Conexeu Sciences Inc., a Nevada corporation (the "Company") having offices at 50 West Liberty Street, Suite 880, Reno, Nevada, USA 89501, and Daniel Bradbury, located at [****]** ("Board Member").**

1. Appointment and Term

1.1 Appointment

The Company hereby appoints the Board Member to serve as a director and Non-Executive Chairman of its Board of Directors (the "Board") effective as of December 1, 2026 (the "Effective Date").

1.2 Term

The Board Member shall serve until the earlier of resignation, removal or the next annual meeting of stockholders, and thereafter if re-elected.

2. Duties and Responsibilities

2.1 General Duties\


The Board Member agrees to serve the Company faithfully and diligently and agrees to act in the best interests of the Company and its stockholders.

2.2 Meetings

The Board Member shall attend all scheduled board meetings (virtually or in person) and actively participate in board and committee matters, subject to reasonable advance notice of such meetings.

2.3 Conflicts of Interest\


The Board Member shall promptly disclose any potential or actual conflicts of interest and shall recuse himself from any discussion or vote where any such conflict exists.


3. Compensation and Reimbursement

3.1 Board Compensation\


As compensation for service as a director and Non-Executive Chairman of the Board, the Board Member shall receive:

i. Annual Retainer. An annual cash retainer of $100,000, comprising a $50,000 base retainer and a $50,000 Non-Executive Chairman premium, per fiscal year of the Company (November 1 to October 31), payable quarterly in arrears in instalments of $25,000, subject to the equity election below.

ii. Equity Election in Lieu of Cash Retainer. For each fiscal year commencing on or after November 1, 2027, the Board Member may make a single written election, delivered to the Company before the beginning of that fiscal year, to receive, in lieu of the $100,000 annual cash retainer for that fiscal year, a grant of shares of common stock under the Company's existing Stock Incentive Plan (the "Plan") having a grant date value of $100,000, to be made up front at the beginning of that fiscal year. The number of shares in each initial or subsequent cash-replacement grant shall equal the applicable grant date value divided by the Fair Market Value (as defined in the Plan) of a share of common stock on the grant date. In the absence of a valid election, the cash retainer shall be paid quarterly in arrears. Each election applies only to the applicable fiscal year and does not replace or reduce the separate annual June 15 RSU grant under Section 3.1.ix.

iii. Initial Equity Election. The Board Member has elected to receive shares of common stock in lieu of cash for the initial fiscal service period from December 1, 2026 to October 31, 2027. The initial grant shall be made on December 1, 2026 with a full grant date value of $100,000, without proration.

iv. Pooling/Lock-Up of Cash-Replacement Shares. The initial and subsequent cash-replacement shares shall be subject to a pooling/lock-up restricting transfer, with 25% of the shares released on each of the four quarterly release dates following the grant date, as set out in the applicable award agreement.

v. One-Time Option Grant.** **The Board Member shall receive a one-time grant on December 1, 2026 of 100,000 non-qualified stock options to purchase an aggregate of 100,000 shares of common stock under the Plan. The exercise price per share shall equal the Fair Market Value (as defined in the Plan) of a share of common stock on December 1, 2026. The stock options shall vest in four equal quarterly instalments of 25,000 stock options following the dates of grant with the first 25,000 stock options vesting on February 28, 2027.

vi. Additional cash compensation will be paid to the Board Member for participation on Committees as set forth in Sections 3.1.vii and 3.1.viii below;


vii. The following annual amount will be paid for membership or chair service on each Committee: 

a. If the Board Member is a member of the Audit Committee: $7,500; Compensation Committee: $6,000; Nominating & Governance Committee: $5,000; and

b. If the Board Member is the Chair of a Committee the following amounts will be paid in lieu of the member amount: Audit Committee Chair: $15,000; Compensation Committee Chair: $12,000; Nominating & Governance Chair $7,500.

viii. Committee service fees shall be paid quarterly in arrears, in conjunction with the quarterly Board Member retainer;

ix. Annual RSU Grant. The Board Member will receive a separate annual grant of restricted stock units ("RSUs") under the Plan on June 15 of each year, with a grant date value of $150,000. The first annual RSU grant shall be made on June 15, 2027 and shall have a prorated grant date value of $81,250 for the initial period from December 1, 2026 to June 15, 2027; subsequent annual RSU grants shall have the full $150,000 grant date value. Each annual RSU grant, including the first prorated grant, shall vest in four equal quarterly instalments of 25% over the 12 months following its grant date, subject to Continuous Service on each applicable vesting date and the terms of this Agreement and the applicable RSU award agreement. The number of RSUs shall be calculated by dividing the applicable grant date value by the Fair Market Value (as defined in the Plan) of the shares of common stock underlying the RSUs on the date of grant rounded down to the nearest whole share. All the outstanding and unvested RSUs held by the Board Member shall fully accelerate immediately prior to the closing of a Change in Control (as defined in the Plan), provided the Board Member remains in Continuous Service through such date (single-trigger) subject to the terms of the Plan. All vesting is subject to the Board Member's Continuous Service on each applicable vesting date, as further described in Section 3.1.x below.

x. Continuous Service; Forfeiture. "Continuous Service" means the Board Member's uninterrupted service as a member of the Board of Directors of the Company. Continuous Service shall be deemed to terminate on the effective date of the Board Member's resignation, removal, or other cessation of board service, not the date on which notice of such resignation or removal is given, unless no such effective date is set forth in the notice. Upon termination of Continuous Service for any reason other than death, disability, or a Change in Control: (a) any RSUs that have not vested as of the effective date of such termination shall be immediately and automatically forfeited without consideration and shall be returned to the Plan; and (b) no pro-rata vesting shall apply to annual RSU grants upon voluntary resignation.

xi. Compensation Committee Discretionary Acceleration. The Compensation Committee of the Board retains the authority, in its sole discretion, to recommend to the Board to accelerate the vesting of any or all outstanding RSU awards in circumstances it determines to be appropriate, including but not limited to: (i) a board restructuring initiated by the Company; (ii) the Board Member's resignation required due to a conflict-of-interest recusal at the Company's request; or (iii) such other circumstances as the Compensation Committee deems equitable. Such acceleration shall not require stockholder approval unless required by applicable law, regulatory or exchange approval or the terms of the Plan.


xii. Death or Disability. In the event of the Board Member's death or permanent disability during the term of this Agreement, all then-outstanding and unvested RSU awards shall vest on a pro-rata basis, calculated as: (months of Continuous Service completed in the applicable vesting period ÷ total months in the vesting period) × total unvested RSUs in that period. Settlement shall occur within 30 days of the qualifying event. For purposes of this Agreement, "permanent disability" means the Board Member's inability to perform the duties of a board member for a period of 180 consecutive days due to physical or mental incapacity, as determined by a licensed physician.

xiii. Director Stock Ownership Guidelines. To promote long-term alignment between the Board and the Company's stockholders, each non-employee director is expected to achieve and maintain a minimum level of equity ownership in the Company equal to five times (5x) the annual cash retainer (the "Ownership Guideline"). Based on the current annual cash retainer of $100,000, the Ownership Guideline is $500,000 in Company equity value. Each non-employee director shall have five (5) years from the later of (a) the Effective Date or (b) the date of any future increase in the Ownership Guideline, to achieve the Ownership Guideline level (the "Phase-In Period").

For purposes of calculating compliance with the Ownership Guideline, qualifying equity shall include: (a) shares of Company common stock owned directly or beneficially by the Board Member or their immediate family members residing in the same household; (b) vested RSUs and vested in-the-money stock options (measured by intrinsic value); and (c) unvested RSUs that are subject only to time-based vesting conditions. Unexercised, out-of-the-money options shall not count toward the Ownership Guideline.

Given that the annual equity grant under Section 3.1.ix has a grant date value of $150,000 (with the first grant prorated to $81,250), a non-employee director who retains their annual equity grants will accumulate equity value of approximately $500,000 within about four years of service, well within the five-year Phase-In Period. The Ownership Guideline is intended to be achievable and is not designed to be punitive or restrictive.

Until the Ownership Guideline is met, the Board Member is expected to retain at least 50% of net shares received upon the vesting or exercise of any Company equity award (after withholding for applicable taxes). Once the Ownership Guideline is achieved, the Board Member is expected to maintain that level of ownership for so long as they serve on the Board. The Compensation Committee shall review compliance with the Ownership Guideline annually and may adjust the Ownership Guideline from time to time to reflect changes in the annual cash retainer or market practice, with any increase subject to a new five-year phase-in from the date of such adjustment.


3.2 Reimbursement

The Company shall reimburse the Board Member for reasonable and documented pre-approved out-of-pocket expenses incurred in connection with Board service subject to prior written approval for any single expense exceeding $500. Reimbursement requests must be submitted within 30 days of the expense being incurred, accompanied by supporting receipts.* *

4. Confidentiality and Intellectual Property

4.1 Confidentiality

The Board Member shall maintain in strict confidence all non-public information, including but not limited to financial data, strategic plans, intellectual property, business opportunities, and customer/vendor relationships,  except as required by applicable law, regulation, or stock exchange rule, or pursuant to a valid court order or subpoena, provided that the Board Member shall give the Company prompt written notice of any such required disclosure and shall cooperate with the Company in seeking any available protective order or other confidential treatment of such information.** **

4.2 Intellectual Property

The Board Member shall promptly disclose to the Company any inventions, improvements, or ideas related to the Business of the Company, including but not limited to, collagen, biomaterials and tissue regeneration (For the purposes of this provision, the "Business of the Company" means the research and development, manufacture, and commercialization of liquid, thermo-sensitive skin substitutes and scaffolds for use in wound healing - including but not limited to burns, tunnel wounds, diabetic foot ulcers and dehiscent wounds - as well as applications in aesthetic medicine, collagen injectables, biomaterials, and in surgical reconstruction as 3D personalized implants or scaffolds for regenerative tissue repair) that arise during their service, and hereby assigns to the Company all rights, title, and interest in any such intellectual property developed in connection with Company business. For the avoidance of doubt, this assignment does not apply to any intellectual property (a) developed by the Board Member entirely prior to the Effective Date; or (b) developed entirely outside of the Board Member's service without use of Company resources, facilities, or Confidential Information.

5. Termination

This Agreement may be terminated:


i. Immediately for "Cause" as defined in Board Member's equity award agreement; or, if no equity award agreement is in effect, "Cause" shall mean: (a) the Board Member's material breach of fiduciary duty; (b) fraud, willful misconduct, or gross negligence; (c) conviction of, or plea of guilty or no contest to, a felony; or (d) material violation of any written Company policy.

ii. Automatically upon the Board Member's resignation, removal, or failure to be re-elected at any Annual Meeting of Stockholders, in each case in accordance with the Company's Bylaws and applicable law.

6.  Notices

All notices, requests, and other communications under this Agreement shall be in writing and shall be delivered: (a) by hand; (b) by nationally recognized overnight courier; or (c) by email with confirmation of receipt, to the addresses set forth on the signature page below (or such other address as a party may designate by written notice). Notices shall be deemed delivered upon receipt.

7. Miscellaneous

7.1 Independent Contractor

The Board Member is an independent contractor and is not an employee of the Company by virtue of this Agreement.

7.2 Governing Law\


This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without regard to its conflict of law principles. The parties hereto irrevocably attorn and submit to the exclusive jurisdiction of the courts of the State of Nevada, sitting in City of Las Vegas, with respect to any dispute related to or arising from this Agreement.

7.3 Entire Agreement\


This Agreement, together with the Plan and any equity award agreement issued hereunder*, *constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, and representations.\


7.4 Amendment

This Agreement may not be amended, modified, or waived except by a written instrument signed by both parties.


7.5 Counterparts

This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Electronic signatures shall be deemed original signatures for all purposes.

[Intentionally Left Blank]


IN WITNESS WHEREOF, the parties have executed this Board Member Agreement as of the date on the first page.

Conexeu Sciences, Inc.

By: /s/ Miles Harrison*                  *

Name: Miles Harrison

Title: Chief Executive Officer

Board Member:

/s/ Daniel M. Bradbury*                 *

Daniel Bradbury

Address:

[****]

[****]


Back to all agreements